You are here

Our science / Clinical Trials / Find a Trial / NCT00895037

Study Evaluating Pharmacovigilance Of Refacto AF

Back to Search Print Save as PDF Bookmark Trial

NCT00895037

Last updated on March 14, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
LKH - Univ. Klinikum Graz,Abt. fur Hamatologie
Graz, , 8036 Austria
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hemophilia A
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with hemophilia A of any severity already receiving or starting treatment
with ReFacto AF.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with Hemophilia A treated with a product other than Refacto AF.

NCT00895037
Pfizer
Completed
Study Evaluating Pharmacovigilance Of Refacto AF

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Hemophilia A
Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine Prophylaxis
NCT02718677
Males
Hemophilia A or B
PF-06741086 Long-term Treatment in Severe Hemophilia
NCT03363321
Males
12+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now